Aptevo Therapeutics (NASDAQ:APVO) issued its earnings results on Tuesday. The biotechnology company reported ($1.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.70), Fidelity Earnings reports.
NASDAQ APVO traded down $2.12 during trading hours on Thursday, reaching $28.40. 614 shares of the company were exchanged, compared to its average volume of 63,867. The company has a quick ratio of 4.13, a current ratio of 4.13 and a debt-to-equity ratio of 11.44. The stock has a market capitalization of $124.36 million, a P/E ratio of -1.87 and a beta of 7.47. The business’s 50 day simple moving average is $34.11 and its 200-day simple moving average is $28.85. Aptevo Therapeutics has a 1 year low of $3.06 and a 1 year high of $60.00.
Separately, Zacks Investment Research lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 8th.
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.